Market access roundup: UK HTA shakeups as Brexit fears deepenWith a Brexit deal still out of sight, there have been intensified warnings in the UK about potential Share XMarket access roundup: UK HTA shakeups as Brexit fears deepenhttps://pharmaphorum.com/views-and-analysis/market-access-roundup-uk-hta-shakeups-as-brexit-fears-deepen/
Biotech in post-Brexit Britain: the future for the UK’s pharma-innovation engine?Drug development can be quite a risky business at the best of times, but particularly in the biotech Share XBiotech in post-Brexit Britain: the future for the UK’s pharma-innovation engine?https://pharmaphorum.com/views-and-analysis/biotech-in-post-brexit-britain-the-future-for-the-uks-pharma-innovation-engine/
Access to new medicines in Scotland: a perennial issueAccess to new medicines in Scotland – just as it would seem is the case everywhere – is Share XAccess to new medicines in Scotland: a perennial issuehttps://pharmaphorum.com/views-and-analysis/access-to-new-medicines-in-scotland-a-perennial-issue/
Cost concerns with the new NHS pricing schemeA new pricing scheme, which took effect this month, has raised the cap on NHS spending on branded Share XCost concerns with the new NHS pricing schemehttps://pharmaphorum.com/views-analysis-market-access/cost-concerns-with-the-new-nhs-pricing-scheme/
Market access roundup: The US fights back against price hikesDon’t expect the US government’s war on drug pricing to go away any time soon – for once Share XMarket access roundup: The US fights back against price hikeshttps://pharmaphorum.com/views-analysis-market-access/market-access-roundup-the-us-fights-back-against-price-hikes/
Mandatory or voluntary? A sticking point for European HTAThe long road to unified European Health Technology Assessment (HTA) is continuing. It has become clear that the Share XMandatory or voluntary? A sticking point for European HTAhttps://pharmaphorum.com/views-analysis-market-access/mandatory-or-voluntary-a-sticking-point-for-european-hta/
2018 in review: Governments start taking access seriouslyMarket access has become a key focus for governments across the globe in 2018 – though as ever Share X2018 in review: Governments start taking access seriouslyhttps://pharmaphorum.com/views-analysis-market-access/2018-in-review-governments-start-taking-access-seriously/
Pharma hopes for best, fears the worst, as Brexit vote nearsThe deadline for Brexit is edging closer, and politicians in the UK are struggling to come to terms Share XPharma hopes for best, fears the worst, as Brexit vote nearshttps://pharmaphorum.com/views-analysis-market-access/pharma-hopes-best-fears-worst-brexit-vote-nears/
Late to the party but we brought friends: BeneLuxA’s horizon scanning initiativeIt can feel good to know what is coming your way; that’s no different for new medicines and Share XLate to the party but we brought friends: BeneLuxA’s horizon scanning initiativehttps://pharmaphorum.com/views-analysis-market-access/joint-horizon-scanning/
